Last reviewed · How we verify

Psychiatric treatment with sertraline

Klinički Bolnički Centar Zagreb · Phase 1 active Small molecule

Psychiatric treatment with sertraline is a Small molecule drug developed by Klinički Bolnički Centar Zagreb. It is currently in Phase 1 development. Also known as: Intervention I.

At a glance

Generic namePsychiatric treatment with sertraline
Also known asIntervention I
SponsorKlinički Bolnički Centar Zagreb
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Psychiatric treatment with sertraline

What is Psychiatric treatment with sertraline?

Psychiatric treatment with sertraline is a Small molecule drug developed by Klinički Bolnički Centar Zagreb.

Who makes Psychiatric treatment with sertraline?

Psychiatric treatment with sertraline is developed by Klinički Bolnički Centar Zagreb (see full Klinički Bolnički Centar Zagreb pipeline at /company/klini-ki-bolni-ki-centar-zagreb).

Is Psychiatric treatment with sertraline also known as anything else?

Psychiatric treatment with sertraline is also known as Intervention I.

What development phase is Psychiatric treatment with sertraline in?

Psychiatric treatment with sertraline is in Phase 1.

Related